PREHEVBRI

This brand name is authorized in Austria, Estonia, Croatia, Ireland, Italy, Lithuania, United Kingdom

Active ingredients

The drug PREHEVBRI contains one active pharmaceutical ingredient (API):

1 Hepatitis B, purified antigen

Hepatitis B vaccine induces specific humoral antibodies against hepatitis B virus surface antigen (anti-HBsAg). Hepatitis B vaccine has been recognized as the first anti-cancer vaccine because it can prevent primary liver cancer.

Read about Hepatitis B, purified antigen

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
J07BC01 Hepatitis B, purified antigen J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BC Hepatitis vaccines
Discover more medicines within J07BC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1882065
Country: IT Agenzia del Farmaco Identifier(s): 050052012
Country: LT Valstybinฤ— vaistลณ kontrolฤ—s tarnyba Identifier(s): 1094657, 1098817

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.